Urology Times staff

"About 30% of women screened positive, but of course when we looked at [the data] stratified by age, about 50% of women 65 years and older had a positive screen," says Steven R. Fisher, PhD, PT, GCS.

"We are optimistic about this study, because it has the potential not just only for vesicovaginal fistula treatment, but it can be also used in the treatment of burns for other fistula types," says Ilaha Isali, MD.

Chandler Park, MD, discusses lessons from the ARASENS and TITAN trials on the use of triplet vs doublet therapy in patients with metastatic hormone-sensitive prostate cancer.

“The first thing I'd say is that we know these devices are safe,” says Colin Goudelocke, MD.

"Our second line [for overactive bladder] is our medications. These often can be very effective for patients, but we find that they can be also extremely limited by adverse events that are associated with those medications," says A. Lenore Ackerman, MD, PhD.

The safety and efficacy of the Vivally System were established in the FREEOAB study, a prospective multi-center clinical trial that included 96 patients with overactive bladder.

“I think clinicians can really take away that we have more work to be done in this space of evaluating patients with microhematuria, specifically when it comes to looking at assessments of upper tract urothelial carcinoma or renal cell carcinoma,” says Jacob Taylor, MD, MPH.

“We want to minimize our negative biopsies and diagnosis of grade group 1 cancers,” says Rashid Siddiqui, MD.

“I would say that these conditions are highly heterogeneous, and we've identified a number of factors that relate to different ways that the disease progresses and different ways that patients feel about the progression of their disease,” says Alisa J. Stephens-Shields, PhD.

“We might find that there's a certain type of patient that really thrives on interacting with the device and playing an active role in his or her therapy,” says Colin Goudelocke, MD.

“What we need now are biomarkers to know if the medication is going to work or not,” says Park.

"Understanding work productivity and activity impairment in the context of the treatment decisions are vital, not just for the provider who has to counsel on treatment benefits and risks, but also to the patient who's making the ultimate decision," says Angela Smith, MD, MS.

“Collagenase [clostridium histolyticum (Xiaflex)] is a really important part of our treatment armamentarium,” says Matthew J. Ziegelmann, MD.

"From a urology provider perspective, we should be discussing this with our patients [with bladder cancer] as they make their treatment decisions," says Angela Smith, MD, MS.

“I think it's important as urologists to try to understand how we fit into this scheme and how we can participate in value-based care in a meaningful way without negatively affecting patients,” says Avinash Maganty, MD.

"If we do not see people that look like us in positions of leadership, that is not a field that we're going to want to enter," says Akanksha Mehta, MD, MS.

Alexandra Sokolova, MD, discusses unanswered questions and next steps with PARP inhibitors in the prostate cancer treatment paradigm.

Arya Mariam Roy, MBBS, discusses the effect of neoadjuvant chemotherapy on overall survival in patients with sarcomatoid bladder cancer.

The phase 2 CaboPoint trial is exploring cabozantinib in patients with locally advanced or metastatic renal cell carcinoma who progressed after first-line checkpoint inhibitor–based combination therapy.

“[Collagenase clostridium histolyticum (Xiaflex)] is an incredibly important part of the treatment armamentarium for Peyronie's disease in the US,” says Matthew J. Ziegelmann, MD.

"The [SWIU meeting] is a meeting that provides updates to all of our members about the exciting initiatives that the organization has been able to accomplish in the preceding year, as well as the initiatives that are planned for the subsequent year," says Akanksha Mehta, MD, MS.

“We do see that the device appears to be clinically efficacious,” says Colin Goudelocke, MD.

"I think there's going to be a rapid adoption of artificial intelligence platforms in our field," says David Sheyn, MD.

"It is a big ask of a trainee to have them sign up for a field that is demanding in terms of training, but also demanding in terms of non-professional commitments that they would otherwise make to their family life and their personal life," says Akanksha Mehta, MD, MS.

“We would like to use all of what we've learned in the MAPP to move back into the space of clinical trials and trying to identify effective therapies for this condition,” says Alisa J. Stephen-Shields, PhD.

“The readers of our paper should really understand that in microhematuria specifically, a lot of the recommendations are based on small amounts of data,” says Jacob Taylor, MD, MPH.

"Where it's feasible and where the patients are eligible, I and others are trying to use alternative therapies, which have probably a similar impact in terms of improving longevity of life for patients [with prostate cancer]," says Praful Ravi, MD, BChir, MRCP.

"The first main finding was after adjusting for individual physician characteristics as well as the characteristics of the actual patient case mix for each physician, we found that small practices performed poorly compared with larger practices," says Avinash Maganty, MD.

“This is a lifetime disease; you want to make sure that the battery not just has long enough life but still has the capacity,” says Colin Goudelocke, MD.

Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.